Dr Muthu Kumaraswamy P K

40+ Years Experience

MD, DM(Oncology) | Medical Oncology

English | Tamil

Overall Rating 4.14

Apollo Speciality Hospitals Madurai

# Apollo Speciality Hospital, Lake View Road, Kk Nagar, Madurai - 625020 Ph:0452-2589904, , Madurai, ,

Get Hospital Directions

Select Date

> Loading available days...

Available Slots:

Book Appointment Request Appointment

Overview

Dr. Muthu Kumaraswamy P K is a highly experienced Medical Oncologist based in Madurai, Tamil Nadu, with an impressive 40 years of expertise in the field of oncology. His extensive qualifications include MD and DM, highlighting his commitment to providing the highest standard of care to his patients. As a male medical professional, Dr. Kumaraswamy is well-regarded in the community for his compassionate approach and his ability to communicate effectively in both English and Tamil. This linguistic versatility allows him to connect with a diverse range of patients, ensuring that they receive the best possible care tailored to their individual needs.

Affiliated with Apollo Hospitals, Dr. Kumaraswamy specializes in diagnosing and treating various types of cancer, using the latest advancements in medical technology and research. His practice includes comprehensive cancer management, including chemotherapy, targeted therapy, and supportive care, all designed to improve patient outcomes and quality of life.

Dr. Kumaraswamy remains dedicated to staying at the forefront of the ever-evolving field of oncology, participating in continuous education and professional development. He is known for his gentle approach and thorough patient consultations, allowing him to address concerns and develop personalized treatment plans.

Patients visiting Dr. Kumaraswamy can expect a caring and professional environment where their health and well-being are prioritized. With a wealth of experience and a passion for helping others, Dr. Muthu Kumaraswamy P K stands out as a trusted Medical Oncologist in the region.

Experience

32 years standing as a physician, with 24 years dedicated to oncology work.
Professional responsibilities included day-to-day patientcare, under graduate clinical teaching, post graduate clinical teaching and clinical research.
Headed department comprising of 40 beds dedicated to medical oncology.
Average in – patient load around 80 per day; with around 40 chemotherapy treatments being administered daily.

Memberships

Organising Secretary for the 9th Biennial National Conference of Indian Society of Medical and Paediatric Oncology, Feb 1997
American Society of Clinical Oncology
Indian Society of Oncology.
Indian Society of Medical and Paediatric Oncology Association of Physicians of India
Association of Physicians of India (Tamilnadu Chapter) Association of Physicians of India (Madurai Chapter)
Madurai Physicians' Foundation
Indian Medical Associaticn (Madurai branch)

Research and Publication

Regular participation at most national oncology meets and physicians meets. Presented many invited lectures and papers. Publications in several International and National Conference proceedings, Journal of the Association of Physicians of India.
Principal Investigator (Madurai): A randomised, phase 2, International multi-institutional study comparing erlotinib - pemetrexed, pemetrexed alone, and erlotinib alone, as second line treatment for non-smoker patients with locally advanced or metastatic non-squamous non-small cell lung cancer; The Lilly H3E-MC-S103 (b) Trial (2010-11).
Principal Investigator (Madurai): A Randomized, Double-Blind, Phase 3, International multi-institutional Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy protocol; The Lilly 14T-MC-JVBA (b) Trial (2011).
Principal Investigator (Madurai): A Phase 3, International multi-institutional Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology; The Lilly H3E-MC-JMIG Trial (2011).